Zheng W, Kim H, Zhao Q
School of Public Health, and Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Toxicol Sci. 2000 Apr;54(2):295-301. doi: 10.1093/toxsci/54.2.295.
The toxicokinetics of manganese (Mn) was investigated in male and female rats either following a single intravenous (iv) or oral dose of MnCl2 (6.0 mg Mn/kg), or following a single oral dose of methylcyclopentadienyl manganese tricarbonyl (MMT) (20 mg MMT/kg or 5.6 mg Mn/kg). The plasma concentrations of manganese were quantified by atomic absorption spectrophotometry (AAS). Upon iv administration of MnCl2, manganese rapidly disappeared from blood with a terminal elimination t1/2 of 1.83 h and CL8 of 0.43 L/h/kg. The plasma concentration-time profiles of manganese could be described by C = 41.9e(-424t) + 2.1e(-0.44t). Following oral administration of MnCl2, manganese rapidly entered the systemic circulation (Tmax = 0.25 h). The absolute oral bioavailability was about 13%. Oral dose of MMT resulted in a delayed Tmax(7.6 h), elevated Cmax (0.93 microg/ml), and prolonged terminal t1/2 (55.1 h). The rats receiving MMT had an apparent clearance (CL/F = 0.09 L/h x kg) about 37-fold less than did those who were dosed with MnCl2. Accordingly, the area under the plasma concentration-time curves (AUC) of manganese in MMT-treated rats was about 37-fold greater than that in MnCl2-treated rats. A gender-dependent difference in toxicokinetic profiles of plasma manganese was also observed. Female rats displayed a greater AUC than that of male rats. Although the apparent volume of distribution of manganese was similar in both sexes, the apparent clearance in males was about twice that observed in females. The results indicated that after oral administration, the MMT-derived manganese displayed higher and more prolonged plasma concentration-time profiles than MnCl2-derived manganese. Thus, MMT-derived manganese appeared likely to accumulate in the body following repeated exposure.
研究了雄性和雌性大鼠静脉注射(iv)或口服单次剂量的氯化锰(MnCl₂,6.0 mg锰/千克),或口服单次剂量的甲基环戊二烯基三羰基锰(MMT,20 mg MMT/千克或5.6 mg锰/千克)后的锰毒代动力学。通过原子吸收分光光度法(AAS)对血浆中的锰浓度进行定量。静脉注射MnCl₂后,锰迅速从血液中消失,终末消除半衰期(t₁/₂)为1.83小时,清除率(CL₈)为0.43升/小时/千克。锰的血浆浓度-时间曲线可用C = 41.9e⁻⁴²⁴ᵗ + 2.1e⁻⁰.⁴⁴ᵗ描述。口服MnCl₂后,锰迅速进入体循环(达峰时间Tmax = 0.25小时)。绝对口服生物利用度约为13%。口服MMT导致达峰时间延迟(7.6小时)、峰浓度升高(0.93微克/毫升)和终末半衰期延长(55.1小时)。接受MMT的大鼠表观清除率(CL/F = 0.09升/小时×千克)比接受MnCl₂的大鼠约低37倍。因此,MMT处理组大鼠血浆中锰的浓度-时间曲线下面积(AUC)比MnCl₂处理组大鼠约大37倍。还观察到血浆锰毒代动力学特征存在性别差异。雌性大鼠的AUC比雄性大鼠大。尽管锰在两性中的表观分布容积相似,但雄性的表观清除率约为雌性的两倍。结果表明,口服给药后,MMT衍生的锰比MnCl₂衍生的锰具有更高且持续时间更长的血浆浓度-时间曲线。因此,反复接触后,MMT衍生的锰似乎可能在体内蓄积。